Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trinity Biotech ( (TRIB) ) just unveiled an update.
On August 20, 2025, Trinity Biotech announced it received regulatory approval to commence offshore and outsourced manufacturing of its flagship TrinScreen™ HIV rapid test. This strategic move is expected to enhance the company’s financial performance by expanding gross margins, freeing up working capital, and reducing fixed costs, thereby supporting broader profitability and growth objectives. The transition to a more cost-effective and scalable production model marks a critical milestone in Trinity Biotech’s transformation strategy, positioning the company for long-term financial health and improved industry positioning.
The most recent analyst rating on (TRIB) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.
The overall stock score is primarily influenced by the company’s weak financial performance, characterized by declining revenues, high debt levels, and negative equity. Technical analysis provides some positive signals with bullish momentum, but the overbought RSI suggests caution. Valuation metrics are unfavorable due to negative earnings and lack of dividends.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently ventured into the wearable biosensor market with the acquisition of Waveform Technologies Inc.’s biosensor assets. Trinity Biotech’s products are used to detect infectious diseases and measure Haemoglobin A1c levels, among other chemistry parameters, and are sold directly in the United States and through international distributors in over 75 countries.
Average Trading Volume: 4,485,619
Technical Sentiment Signal: Hold
Current Market Cap: $28.34M
Find detailed analytics on TRIB stock on TipRanks’ Stock Analysis page.